Mel Hayes
2023
In 2023, Mel Hayes earned a total compensation of $2.2M as Executive Vice President, Patient Affairs at Fulcrum Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $160,300 |
|---|---|
| Option Awards | $1,561,354 |
| Salary | $471,200 |
| Total | $2,192,854 |
Hayes received $1.6M in option awards, accounting for 71% of the total pay in 2023.
Hayes also received $160.3K in non-equity incentive plan and $471.2K in salary.
Rankings
In 2023, Mel Hayes' compensation ranked 473rd out of 2,978 executives tracked by ExecPay. In other words, Hayes earned more than 84.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 473 out of 2,978 | 84th |
Division Manufacturing | 271 out of 1,637 | 83rd |
Major group Chemicals And Allied Products | 186 out of 906 | 80th |
Industry group Drugs | 183 out of 869 | 79th |
Industry Pharmaceutical Preparations | 114 out of 627 | 82nd |
Source: SEC filing on April 19, 2024.
Hayes' colleagues
We found five more compensation records of executives who worked with Mel Hayes at Fulcrum Therapeutics in 2023.
2023
Alex Sapir
Fulcrum Therapeutics
Chief Executive Officer
2023
Curtis Oltmans
Fulcrum Therapeutics
Chief Legal Officer
2023
Alan Musso
Fulcrum Therapeutics
Chief Financial Officer
2023
Bryan Stuart
Fulcrum Therapeutics
Chief Executive Officer
2023
Robert Gould
Fulcrum Therapeutics